![]() ![]() Sebree co-founded and served as President of NuPathe (Nasdaq: PATH), which was acquired by Teva Pharmaceuticals in February 2014. She has completed more than 10 regulatory submissions and approvals of new pharmaceutical products, including transdermal patch and gel products. Sebree has more than 35 years of executive, development and operational experience in the biopharmaceutical industry, particularly in CNS product development. Sebree has served as our President since October 2014. Anido earned a BS in Pharmacy and an MBA from West Virginia University. He formerly served as a director of Aviragen Therapeutics, a pharmaceutical company, from October 2015 to March 2018, Respira Therapeutics, Inc., a pharmaceutical company, from May 2012 through September 2014, and Adolor Corporation, a pharmaceutical company, from September 2003 through December 2011. a pharmaceutical company, and has held such position since January 2019. Anido currently serves as a director of Altamira Therapeutics (formerly Auris Medical), a pharmaceutical company, and has held such position since April 2016, and as a director of Scynexis, Inc. At GlaxoWellcome, he was Vice President, Central Nervous System Marketing, responsible for the commercialization of the epilepsy, migraine and depression businesses in the U.S. Anido served as Executive Vice President, Sales and Marketing, at MedImmune and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. ![]() He also served as President and CEO of Auxilium Pharmaceuticals (Nasdaq: AUXL), where under his leadership, sales grew from $42 million in 2005 to more than $260 million in 2011 and market capitalization increased from $200 million to more than $900 million. At NuPathe, he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine, to pre-launch before successfully selling the company to Teva. Most recently, he was the CEO of NuPathe (Nasdaq: PATH), which was acquired by Teva Pharmaceuticals in February 2014. ![]() Anido served as CEO of two publicly traded companies. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry, particularly in leading CNS transdermal patch and gel products through the entire product life cycle. Chairman of the Board and Chief Executive OfficerĪrmando Anido has served as our Chairman and Chief Executive Officer (CEO) since October 2014. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |